Cohort description
| Phenotypes | Control | IBD | P value |
| 255 | 424 | ||
| Age (mean (SD)) | 46.83 (12.08) | 42.61 (14.69) | <0.001 |
| Body mass index (mean (SD)) | 25.17 (3.84) | 25.44 (5.02) | 0.462 |
| Sex=male (%) | 114 (44.7) | 170 (40.1) | 0.272 |
| Diagnosis (%) | |||
| CD | NA | 238 (56.1) | |
| IBDU | NA | 12 (2.8) | |
| UC | NA | 174 (41.0) | |
| Disease location (%) | |||
| Both | NA | 97 (22.8) | |
| Colon | NA | 228 (53.7) | |
| Ileum | NA | 69 (16.2) | |
| Disease acitvity (%) | |||
| Active | NA | 107 (25.2) | |
| Not active | NA | 311 (73.3) | |
| Estimated bowel movement a day (mean (SD)) | 1.33 (0.66) | 2.73 (2.37) | <0.001 |
| Smoker=yes (%) | 38 (14.9) | 87 (20.5) | 0.084 |
| Faecal calprotectin >200 = yes (%) | 8 (3.2) | 168 (45.0) | <0.001 |
| Montreal B (%) | |||
| B1 | NA | 129 (54.2) | |
| B2 | NA | 76 (31.9) | |
| B3 | NA | 28 (11.7) | |
| Montreal B perianal (%) | |||
| No | NA | 326 (76.8) | |
| Yes | NA | 68 (16.0) | |
| Montreal S (%) | |||
| S0 | NA | 7 (4.0) | |
| S1 | NA | 56 (32.1) | |
| S2 | NA | 69 (39.6) | |
| S3 | NA | 27 (15.5) | |
| Montreal A (%) | |||
| A1 | NA | 54 (12.7) | |
| A2 | NA | 245 (57.7) | |
| A3 | NA | 85 (20.0) | |
| Montreal L (%) | |||
| L1 | NA | 63 (14.8) | |
| L2 | NA | 203 (47.8) | |
| L3 | NA | 94 (22.1) | |
| L4 | NA | 21 (4.9) | |
| Montreal E (%) | |||
| E1 | NA | 21 (12.0) | |
| E2 | NA | 57 (32.7) | |
| E3 | NA | 80 (45.9) | |
| Microbiome Shannon Index (mean (SD)) | 3.05 (0.33) | 2.89 (0.41) | <0.001 |
CD, Crohn’s disease; IBD, inflammatory bowel disease; IBDU, inflammatory bowel disease unclassified ; NA, not available; UC, ulcerative colitis.